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INTRODUCTION 
 
 
 
 
 
  
INTRODUCTION 
Heart failure is one of the leading causes of hospitalizations throughout the world. Prevalence is 
1% between the ages of 50 and 59 years, progressively increasing to >10% over age of 80 years. 
Concomitant and significant renal dysfunction is common in patients with heart failure.  
Increasingly, the syndrome of heart failure is one of the cardiorenal failure, in which concomitant 
cardiac and renal dysfunctions exist, with each accelerating the progression of the other. One 
fourth of patients hospitalized for  the  treatment  of  acute  decompensated heart failure will 
experience significant  worsening of renal  function, which  is  associated with worse  outcomes.   
It remains unclear whether worsening renal function specifically contributes to poor outcomes or 
whether it is merely a marker of advanced cardiac and renal dysfunction. Diuretic resistance, 
with or without worsening renal  function,  is also common in acute  decompensated heart  
failure,  although the definition of diuretic  resistance, its prevalence, and prognostic implications 
are less well defined 
(1)
.  
The term cardiorenal syndrome has been variably associated with cardiorenal failure, worsening 
renal function, and diuretic resistance but is more comprehensively defined as a state of 
advanced cardiorenal dysregulation manifest by one or all of these specific features.   
The pathophysiology of the cardiorenal syndrome is poorly understood and likely involves 
interrelated hemodynamic and neurohormonal mechanisms. When conventional therapy for 
acute decompensated heart failure fails, mechanical fluid removal via ultrafiltration, 
hemofiltration, or hemodialysis may be needed for refractory volume overload. While 
ultrafiltration can address diuretic resistance, whether ultrafiltration prevents worsening renal 
  
function or improves outcomes in patients with cardiorenal syndrome remains unclear. Newer 
therapeutic agents, including nesiritide, vasopressin antagonists and adenosine antagonists, hold 
promise for the future, and clinical trials of these novel agents are underway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
AIM OF THE STUDY 
 
 
 
 
  
AIM OF THE STUDY 
To do a cross sectional study on the prevalence, predictors and short term outcome in patients 
with heart failure and cardiorenal dysfunction(cardiorenal syndrome) with regard to variations in 
Demographic characteristics 
Etiologic factors 
Severity of cardiac dysfunction 
Associated risk factors 
Treatment factors and 
Outcome difference during hospital stay and 2 month follow up 
                                                                                                                             
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
  
REVIEW OF LITERATURE 
The term cardiorenal syndrome has been variably defined but can be considered as a state of 
advanced cardiorenal dysregulation manifest by one or more of three specific features,  
including  heart  failure with concomitant and significant renal disease (cardiorenal  failure), 
worsening  renal function  (developing during the  treatment  of  acute  decompensated HF), 
and diuretic resistance (Table 1)
(1)
. 
Cardiorenal 
failure 
 
Mild: HF + eGFR 30–59 mL/min/1.73 m2 
Moderate: HF + eGFR 15–29 mL/min/1.73 m2 
Severe HF + eGFR <15 mL/min/1.73 m2 or Dialysis 
Worsening renal function during treatment of ADHF 
Change in creatinine  >0.3 mg/dL or >25% baseline 
Diuretic 
Resistance 
Persistent  congestion despite                                            
>80 mg furosemide/day                                                   
>240 mg furosemide/day (continuous  furosemide infusion) 
Combination diuretic therapy (loop diuretic + thiazide + 
aldosterone antagonist) 
       Table 1: Features of Cardiorenal Syndrome 
The strong connection between renal and cardiovascular disease reflects the complex 
interactions between heart and kidneys. Arthur Guyton first extensively described normal 
physiological interactions between the control of extracellular fluid volume by the kidney 
and systemic circulation by the heart 
(2)
. However, the pathophysiological mechanisms 
underlying this reciprocal relationship between the heart and the kidneys are still ambiguous. A 
diseased heart has numerous adverse effects on kidney function, while in parallel, renal 
  
dysfunction can significantly impair cardiac function 
(3)
 
The so called cardiorenal syndrome is defined as a pathophysiological disorder of the heart and 
kidneys in which acute or chronic dysfunction in one organ may induce acute or chronic 
dysfunction in the other organ. This syndrome has recently been classified into 5 types
(4)
. 
TYPE 1 CARDIORENAL SYNDROME is the most common and is characterized by a rapid 
worsening of cardiac function (pulmonary edema, acutely decompensated chronic heart 
failure, cardiogenic shock, and predominant right ventricular failure), leading to acute kidney 
dysfunction. In this setting, acute kidney injury is more severe in patients with impaired left 
ventricular ejection fraction compared with those with preserved left ventricular function, 
having an incidence >70% in patients with cardiogenic shock. Early diagnosis of acute 
kidney injury remains a challenge and novel biomarkers have shed light in this direction. 
Neutrophil gelatinase-associated lipocalin (NGAL) appears to be one of the earliest markers 
detected in the blood and urine of humans with acute kidney injury in different clinical settings, 
including contrastinduced nephropathy. Notably, in these patients with acute renal dysfunction, 
an increase in creatinine levels is observed only 48 to 72 hours after detection of NGAL.
(5)
  
Furthermore, cystatin C appears to be a better predictor of glomerular function than serum 
creatinine in patients with chronic kidney disease, because its blood levels are not affected by 
age, gender, race, or muscle mass.
(6) Cystatin C also predicts acute kidney injury at 12 hours, 
although NGAL outperformed cystatin C at earlier time points. Considering them together, 
they represent a combination of structural and functional damage to the kidney. 
 
  
PATHOPHYSIOLOGICAL  INTERACTIONS BETWEEN HEART AND KIDNEY 
 
Adapted from The AJCCVol 52 No:19, 2008 State-of-the-art Paper: Cardiorenal Syndrome 
TYPE 2 (CHRONIC) CARDIORENAL SYNDROME is characterized by chronic 
abnormalities in cardiac function causing progressive renal dysfunction, with a prevalence 
around 25%. Independent predictors of worsening renal function include old age, 
hypertension, diabetes mellitus, and acute coronary syndromes 
(7)
. 
Hypoperfusion alone cannot explain the pathophysiology of renal dysfunction in this type of 
cardiorenal syndrome. The ESCAPE trial found a significant relation between right atrial 
pressure measured during pulmonary artery catheterization  and serum creatinine, indicating 
the important role of renal congestion
(8)
. 
  
TYPE 3 ACUTE RENO CARDIAC SYNDROME, less common than type 1, is characterized 
by an abrupt and primary worsening of kidney function, leading to acute cardiac dysfunction 
(e.g. heart failure, arrhythmia, ischemia). Based on the RIFLE  consensus definition (risk, 
injury, failure; loss; end-stage kidney disease), acute kidney injury has been identified in 
9% of hospital patients and in 35% of ICU patients.
(9) Mechanisms underlying impairment 
of cardiac function through acute kidney injury include fluid overload leading to pulmonary 
edema, hyperkalemia causing arrhythmias, and uremia affecting myocardial contractility. 
Finally, renal ischemia itself may precipitate activation of inflammation and apoptosis at the 
cardiac level. 
CHRONIC RENOCARDIAC SYNDROME (TYPE 4) is characterized by a condition of 
primary chronic kidney disease contributing to decreased cardiac function, ventricular 
hypertrophy, diastolic dysfunction, and/ or increased risk of adverse cardiovascular events. 
According to current diagnostic criteria for chronic kidney disease, at least 10% of the general 
adult population suffers from this major public health problem
 (10)
. 
More than 50% of deaths in end-stage renal disease cohorts are attributed to cardiovascular 
disease. In addition, patients with severe forms of chronic kidney disease have a 10 to 20-fold 
increased risk of cardiac death compared to the general population, while even less severe 
forms of chronic kidney disease may be associated with significant cardiovascular risk
(11)
, 
documenting an inverse relationship between renal function and adverse outcome 
(consistently occurring at estimated glomerular filtration rate levels <60 ml/min/1.73m2). In 
this context, data derived from our institution show that parallel cardiac and renal 
involvement in hypertensive individuals without overt cardiovascular disease is associated with 
  
a very high risk of future cardiovascular events.
(12) Part of this increased risk in patients with 
chronic kidney disease is attributed  to under-treatment and less chance to receive risk-
modifying interventions. Potential reasons for this sub-therapeutic performance include 
concerns about further worsening of renal function, and/or therapy-related toxic effects due 
to low clearance rates.  
 
 
 
Additional Risk Factors for Cardio-Vascular Disease in Patients 
with Renal Disease 
 
  
Finally SECONDARY (TYPE 5) CARDIORENAL SYNDROME is characterized by the 
presence of combined cardiac and renal dysfunction due to acute or chronic systemic 
disorders. In the acute setting, severe sepsis represents the most common and serious 
condition that can affect both organs. 
Necessary to offer the best therapy to these patients demands a multidisciplinary approach, 
combining the expertise of cardiology, nephrology, and critical care, as was highlighted in the 
recent international symposium on “Renal dysfunction and cardiovascular diseases 2010” that 
took place in Athens. In conclusion, more attention needs to be paid to reducing risk factors 
for the cardiorenal syndrome.  
 
 
 
 
 
 
 
 
 
  
 
 
Classification of cardiorenal syndrome proposed by Ronco and colleagues 
(13)
 
 
Type 
 
Name 
 
Mechanism 
 
Clinical 
Conditions 
 
 
         
 
Type I 
 
Acute 
Cardiorenal 
syndrome 
 
Abrupt worsening of kidney function  
leading to acute kidney injury 
 
Acute cardiogenic  
shock and acutely  
decompensated  
congestive heart  
failure 
  
ET-1 
Troponin 
Type II 
Chronic 
Cardiorenal 
syndrome 
Chronic abnormalities in kidney function 
causing progressive and potentially 
permanent kidney disease 
Chronic congestive 
heart  failure 
 ET-1, BNP 
 
Type III 
Acute 
Renocardiac 
syndrome 
 
Abrupt worsening of kidney function causing 
acute cardiac disorder 
 
Acute kidney ischemia 
and 
glomerulonephritis 
 
TNF-α,IL-1 
 IL-6, IL-8 
 
Type IV 
Chronic 
Renocardiac 
syndrome 
 
Chronic kidney disease contributing  
to decline in cardiac function 
 
Chronic glomerular 
and Interstitial disease 
 
PTH, CPP 
product 
Cystatin C 
 
Type V 
 
Secondary 
Cardiorenal 
syndrome 
 
Systemic condition causing both  
cardiac and kidney dysfunction 
 
Diabetes mellitus, 
Sepsis 
 --- 
        
*ET-1 indicates endothelin-1;CPK-MB, creatine phosphokinase-MB; BNP, B-type natriuretic peptide; TNF, 
tumor-necrosis factor; IL, interleukin; PTH, parathyroid hormone; and CPP, calcium-phosphate product.  
 
  
THE CARDIO-RENAL CONNECTORS 
 
 
 
Bongartz and colleagues recently proposed an extension to the Guytonian model of volume and 
blood pressure control called “the cardiorenal connection.” Actions of the regulators of Guyton’s 
model were coupled to their extended actions on structure and function of the heart and the kidney. 
Thus, it can be stated that “when one of the organs fails, a vicious circle develops in which the 
RAAS, the NO-ROS balance, the sympathetic nervous system, and inflammation interact and 
synergize, called the “cardiorenal connection” 
 
 
 
  
CARDIORENAL FAILURE 
Renal impairment in patients with HF is increasingly recognized as an independent risk factor for 
morbidity and mortality 
(14)
. In an analysis of patients enrolled in the CHARM study 
(Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Hillege et 
al. showed that the level of renal dysfunction was a potent independent predictor of death or HF 
admission 
(15)
.  
The Acute Decompensated Heart Failure National Registry (ADHERE), a large database of 
105,388 patients with HF requiring hospitalization in the  United States,  reported  that 30% had 
an additional diagnosis consistent with chronic kidney disease
(16)
. Approximately 20% of 
patients had serum creatinine (Cr) >2.0 mg/dL, 9% had Creatinine >3.0 mg/dL, and 5% were 
receiving dialysis therapy.  
Smith et al.
(17)
 conducted a systematic review and meta-analysis of 16 studies characterizing the 
association between renal impairment and mortality in 80,098 hospitalized and nonhospitalized 
HF patients (1945 through May 2005). Renal impairment was defined variably as Cr >1.0 
mg/dL, Cr clearance (CrCl) or estimated   glomerular filtration   rate (eGFR) <90   mL/min,  or 
cystatin-C >1.03 mg/dL. Moderate to severe renal impairment was defined as Cr 1.5 mg/ dL, 
CrCl or eGFR <53 mL/min, or cystatin-C 1.56 mg/dL. A total of 63% of patients had any renal 
impairment, and 29% had moderate to severe impairment. Adjusted all-cause mortality was 
significantly increased for patients with any renal impairment. Mortality worsened incrementally 
across the range of renal function, with 15% increased risk for every 0.5 mg/dL increase in Cr 
and 7% increased risk for every 10 mL/min decrease in eGFR 
(18)
. 
Owan et al. 
(19)
 recently reported  on secular  trends  in  the  severity  of renal dysfunction  in  
  
patients  with  ADHF in 6,440 consecutive unique patients hospitalized  for  HF  therapy  at  
Mayo Clinic Hospitals, Rochester,  MN, from January1, 1987, to December 31, 2002. Over the 
16-yr time period, age and admission Cr increased, eGFR decreased, and hemoglobin decreased. 
The more  dominant role of renal dysfunction in HF was also stressed in the recent Evaluation 
Study of Congestive  Heart Failure  and pulmonary  Artery Catheterization  
Effectiveness(ESCAPE) trial, where it was emphasized that  episodes of HF decompensation 
were less commonly associated with uncorrected vasoconstriction and more commonly 
associated with renal dysfunction  with requirement of higher diuretic  doses at discharge  than  
historically noted 
(20)
.  Thus, the severity of cardiorenal failure in patients hospitalized for HF is 
increasing. Importantly, cardiorenal failure is equally prevalent in patients with HF and normal 
ejection fraction (diastolic HF) or reduced ejection fraction (systolic HF) 
(18, 21)
 
 
WORSENING RENAL FUNCTION 
Several studies have established that >70% of patients will experience some increase in 
Creatinine during hospitalization for HF, with approximately 20% to 30% of HF patients  
experiencing  an increase  of >0.3 mg/dL (19, 21). Worsening renal function occurs relatively 
early in the course of the hospitalization 
(22)
. Any change in Cr has been shown to be associated 
with longer length of stay, increased costs, and increased short-term and long-term mortality. 
The association of worsening renal function with poorer outcomes is independent of the degree 
of baseline renal dysfunction and many other pertinent covariables 
(23, 24)
. Nonetheless, it remains 
unclear whether the worsening renal function itself contributes to the increased mortality or 
whether it merely serves as a marker of more severe cardiac and/or renal dysfunction.  
  
Importantly, worsening renal function is as common in diastolic HF as it is in systolic HF. While 
the severity of underlying renal dysfunction in ADHF patients has increased over time, Owan et 
al. 
(19) 
did not find any evidence of increases in the incidence of worsening renal function over 
time. 
DIURETIC RESISTANCE 
In patients with ADHF associated with volume overload, initial therapy focuses on sodium and 
fluid restriction and diuretics.  Diuretic resistance has been defined as persistent pulmonary 
congestion with or without worsening renal function despite attempts at dieresis (Table 1).  
The prevalence of diuretic resistance (DR) depends in part on the aggressiveness of the diuretic 
dosing. While worsening renal function commonly develops in the absence of persistent 
congestion when diuretic dosing has been too high (termed overdiuresis), worsening renal 
function also often occurs despite persistent pulmonary congestion in patients with diuretic 
resistance. Both DR and worsening renal function (WRF) are more common in patients with 
underlying renal dysfunction, and the triad of cardiorenal failure, DR, and worsening renal 
function despite marked persistent volume overload represents the most extreme manifestation of 
the cardiorenal syndrome.  
Two disparate analyses appeared in the Journal of American college of Cardiology in February 
2009 issue: one  evaluates hemodynamics  associated with  worsening renal  function  (WRF) in  
145  patients  hospitalized  for acutely decompensated heart failure (ADHF)
(25)
, and the other 
assesses the correlation between hemodynamics, renal function, and mortality in 2,557 patients 
undergoing right heart catheterization for various cardiovascular disorders 
(26)
. Despite the 
  
dissimilar patient populations, a strikingly similar message emerges: increased central venous 
pressure (CVP) is independently associated with renal dysfunction, WRF, and unfavorable 
outcomes. In the Dutch study, the detrimental effect of CVP on renal function and survival was 
greatest in those patients with preserved cardiac index (CI) 
(26)
. 
The discordance between cardiac performance and renal function challenges the notion that, in 
heart failure (HF), renal insufficiency usually represents hypoperfusion of the kidney as the 
result of poor forward flow or overzealous diuresis. Instead, growing evidence shows that 
hypervolemia by itself is independently associated with mortality 
(27)
.  The authors of a  study 
comparing  blood  volume measured by radiolabeled albumin with hemodynamics and outcomes 
in 43 nonedematous patients with HF  demonstrated that 65% were hypervolemic 
(28)
. 
Importantly, blood volume was closely correlated with pulmonary capillary wedge pressure 
(PCWP) and independently predicted 1-year risk of death or urgent cardiac transplantation, both 
significantly greater in the hypervolemic patients 
(28)
. Observational data in patients with ADHF 
showed that pre-discharge reduction of PCWP <16 mm Hg, as opposed to an increased CI, 
predicted improved 2-year survival. Interestingly, in the Dutch  study,  increased  CVP  on  
admission,  as  well as insufficient reduction of CVP during hospitalization, were the  strongest 
determinants  for the  development of WRF 
(25)
. In contrast, impaired CI on admission and 
improvement in CI after intensive medical therapy had little effect on WRF.  These intriguing 
observations raise questions about our current management strategy for acute HF, which has 
been to lower cardiac filling pressures while maintaining or enhancing CI 
(29)
. What are the 
mechanisms by which venous congestion worsens renal function, and why is vigorous diuresis 
alone so often ineffective?  
  
Normally, 85% of the total plasma volume resides in the venous circulation; only 15% is 
maintained in the arterial circuit. The primary regulation of renal sodium and water excretion 
and, thus, body fluid homeostasis, is modulated by the smaller arterial circulation, enabling the 
system responsible for the perfusion of the body’s vital organs to respond to small changes in 
body fluid volume 
(30)
. Heart failure results in a decrease in CI and a decrease in intra-arterial 
blood volume. Arterial hypovolemia inactivates the high pressure baroreceptors in the aortic 
arch and coronary sinus, attenuates the tonic inhibition of afferent parasympathetic signals to the 
central nervous system, and enhances sympathetic  efferent  tone,  with  subsequent  activation  
of  the renin-angiotensin-aldosterone  system (RAAS)  and  non osmotic release of arginine-
vasopressin (AVP)
(30)
. In the kidney, increased angiotensin II (Ang II) causes renal efferent 
arteriolar vasoconstriction, resulting in decreased renal blood flow (RBF) and increased 
filtration fraction. Together with renal nerve stimulation, the increased peritubular capillary 
oncotic pressure and reduced peritubular capillary hydrostatic pressure augment sodium 
reabsorption in the proximal tubule. Angiotensin II also directly stimulates proximal sodium 
reabsorption by activating sodium bicarbonate cotransporters and apical sodium-hydrogen 
exchangers. Finally, Ang II promotes aldosterone secretion, which boosts sodium reabsorption 
in the distal nephron 
(30)
. Importantly, increased proximal sodium reabsorption decreases distal 
sodium and water delivery, stimulating macula densa cells to increase synthesis of renin that 
further amplifies neurohormonal activation 
(31)
. Enhanced renal sodium and water reabsorption 
predominantly fills the compliant venous circulation, increasing CVP and atrial pressures. 
Normally, an increase in atrial pressure suppresses AVP release and enhances water diuresis, 
decreases renal sympathetic tone, and augments natriuretic peptide secretion. In patients with 
HF, these atrial–renal  reflexes  are  overwhelmed by neurohormonal  activation,  evidenced by  
IMPACT OF VENOUS CONGESTION ON GLOMERULAR NET FILTRATION PRESSURE
  
 
persistent renal sodium and water retention despite elevated atrial pressures 
(30)
. Transmission of 
venous congestion to the renal veins further impairs the glomerular filtration rate (GFR) (See 
Figure).  
The authors of an isolated mammalian kidney study from 1931 showed that increased renal 
venous pressure was associated with reduced RBF, urine flow, and urinary sodium chloride 
excretion, abnormalities that were reversed by lowering renal venous pressure 
(32)
. Years later, 
hypervolemia experimentally induced in dogs directly decreased GFR, independent of CI and 
RBF (33). A contemporary study in patients with ADHF   revealed that an increased intra-
abdominal pressure from ascites and visceral edema was correlated with the severity of renal 
dysfunction and that reduction of intra-abdominal pressure improved renal function 
(34)
. 
Furthermore, in the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary 
Artery Catheterization Effectiveness) trial, right atrial pressure emerged as the only 
hemodynamic variable correlated with baseline renal function, an independent  predictor of 
mortality and HF  hospitalization 
(35)
.  
Despite these provocative data, it is premature to conclude that therapies specifically aimed at 
the reduction of CVP will actually reduce renal dysfunction or mortality in patients with HF.  In 
the ESCAPE trial, therapy directed toward lowering measured PCWP and CVP produced no 
better outcomes than management aimed to reduce exam-based CVP 
(35)
. Also unknown are the 
specific CVP values that must be achieved to improve renal function and outcomes. Perhaps the 
strategy to reduce filling pressures in HF remains appropriate, but our heavy reliance on the 
tactic of diuretics to achieve this goal may critically impact renal function and outcome. Loop 
  
diuretics act in the thick, ascending limb of the loop of Henle, near the macula densa. Loop 
diuretics block sodium chloride uptake in the macula densa, independent of any effect on 
sodium and water balance, thereby stimulating the RAAS 
(36)
. This pathophysiology, and the 
growing literature documenting the adverse consequences of diuretic use on ADHF outcomes 
(37)
, has lead to exploration of other approaches. If fluid removal by an alternative therapy, such 
as ultrafiltration, does not exceed the interstitial fluid mobilization rate of 14 to 15 ml/min, 
further activation of the RAAS is avoided. Moreover, for the same fluid volume, more sodium is 
removed by isotonic ultrafiltration than by diuretic-induced hypotonic diuresis 
(38)
. Data from 
the UNLOAD (Ultrafiltration vs IV Diuretics for Patients Hospitalized for Acute 
Decompensated Congestive Heart Failure) trial on ADHF rehospitalization rates after 
ultrafiltration appear promising and await further confirmation in larger trials 
(39)
. 
 
RISK FACTORS FOR CARDIORENAL SYNDROME 
The common risk factors of hypertension, diabetes mellitus, and atherosclerosis explain the high 
prevalence of coexistent cardiac and renal dysfunction. Success in preventing death from HF, 
acute myocardial infarction, stroke, and non cardiovascular disease may result in a longer 
exposure to risk factors for renal dysfunction contributing to more severe renal dysfunction in 
HF patients. Importantly, CrCl or eGFR as estimated by the simplified Modification of Diet in 
Renal Disease formula or Cockcroft-Gault formula is a better estimator  of renal function  than 
serum Cr, as serum Cr may overestimate renal function  in the HF population, particularly  in  
elderly women. On average, persons developing worsening renal function are older and have a 
greater prevalence of prior HF, renal dysfunction, diabetes, and hypertension. 
  
APPROACH TO THE CARDIORENAL SYNDROME 
The development of worsening renal function and/or DR during the treatment of the patient with 
cardiorenal failure is a common and predictable but difficult clinical problem. There is no 
consistently effective strategy, and much of the approach is empirical. 
APPROACH TO THE CARDIORENAL SYNDROME 
1 Anticipate 
2 Optimize Heart Failure therapy 
3 
Evaluate renal structure and function 
(ultrasonography  accompanied by renal vascular 
evaluation with Doppler and resistive indices) 
4 Optimize diuretic dosing 
5 
Consider renal-specific therapies 
a.  Renal-dose dopamine 
b.  Nesiritide 
c.  Ultrafiltration and/or hemodialysis 
6 
Investigational therapies 
a.  Hypertonic saline + high-dose loop diuretics 
b. Vasopressin antagonists 
c.  Adenosine antagonists 
RECOGNIZE THE CARDIORENAL SYNDROME AND ANTICIPATE THE 
DEVELOPMENT OF WORSENING RENAL FUNCTION 
Patients developing the cardiorenal syndrome in the setting of ADHF and persistent congestion 
are usually those with long-standing HF who experience an episode of decompensation despite 
adequate chronic HF therapy and who are already on chronic high-dose diuretic therapy. A 
progressive increase in Cr over recent years is typically evident and reflects not only the 
  
underlying renal disease but the additional effect of the HF state as outlined previously. Patients 
with severe diastolic dysfunction (regardless of ejection  fraction),  secondary pulmonary 
hypertension,  right  ventricular  dysfunction, marked functional  tricuspid  or mitral 
regurgitation, previous HF hospitalizations, a history of worsening renal function with 
previous ADHF episodes, or a history of transient  dialysis (often after cardiac surgery or 
contrast administration)  are  at  the  highest  risk.  In many patients, development of the 
cardiorenal syndrome is a marker of the transition to stage D HF (See Figure). It is helpful to 
address  the  potential  for worsening  renal function with the patient at admission, including  
the prognostic  implications  of cardiorenal  syndrome  and  stage  D. An assessment of 
suitability for dialysis and advanced HF therapies, such as cardiac support (left ventricular 
assist device) or replacement (transplantation), should be made. 
 
Development of the cardiorenal syndrome as a marker of the transition to stage D heart failure 
  
Unfortunately, the vast majority of patients developing cardiorenal syndrome will not be 
candidates for advanced HF treatments, such as transplantation or left ventricular   assist 
device, due to age and comorbidities. Anticipation of a very high risk for cardiorenal syndrome 
may support use of different strategies, such as more gradual volume removal or early use of 
(potentially) renal-protective strategies (discussed subsequently). However, whether slower 
volume removal or the variety of strategies available to preserve renal function will affect the 
development of the cardiorenal syndrome or improve outcomes is unknown. 
 
OPTIMIZE HEART FAILURE THERAPY 
While therapy for ADHF often focuses on volume removal, careful review of the patient’s HF 
therapy addressing the adequacy of vasodilator therapy, blood pressure control, or the potential 
for additional adjuvant therapy (digoxin, nitrates, cardiac resynchronization therapy) is 
important. Addressing factors that can provide additional symptom relief (paracentesis, 
thoracentesis) or optimize cardiac function (revascularization, correction of valve disease) should 
be considered early in the hospitalization. Many centers are still aggressive in the use of 
pulmonary artery catheters in difficult patients with cardiorenal syndrome to ensure that 
hemodynamics and standard HF therapies are optimized. Importantly, pulmonary artery catheter 
guided therapy commonly includes administration of an inotropic agent. Use of inotropic agents 
is consistently associated with poorer outcomes, whether in randomized trials or retrospective 
registries, and their ability to improve cardiac status in the hospital must not be equated with 
improved outcomes 
(40, 41)
. 
  
 
EVALUATE RENAL STRUCTURE AND FUNCTION 
A careful history should identify factors that may be exacerbating disease and HF related renal 
dysfunction, such as infection, use of nephrotoxic agents, or risk factors for renal artery 
stenosis. Urinalysis, including microscopic analysis for urine  eosinophils (seen in allergic 
interstitial nephritis or renal atheroembolism), renal ultrasound  with Doppler imaging of renal 
arteries, and assessment of renal resistive indices, should be performed to assess renal size, 
renal artery stenosis, or obstruction  and to characterize structural renal  disease. If suspicion 
for renal artery stenosis is high, one can consider magnetic resonance imaging with 
angiography, although this is increasingly difficult in patients with systolic HF due to the 
presence of devices. Computed tomography angiography to assess for renal artery stenosis is 
often precluded because of the potentially high risk of contrast nephrotoxicity and renal 
atheroembolism. The risk-benefit ratio of contrast administration must be weighed carefully as 
even gadolinium (used with magnetic resonance angiography) carries risk of worsening renal 
function in HF patients. The role of renal biopsy has not been well defined in this setting, and 
clearly the risk-benefit ratio must be considered on an individual basis. However, in patients 
in whom the cause of acute renal failure is unclear even after a thorough history, physical 
examination, and laboratory and clinical investigations are performed, renal biopsy may 
provide definitive diagnostic information that is helpful in guiding therapy or prognosis. 
OPTIMIZE DIURETIC DOSING 
Continuous infusion of loop diuretics (i.e., furosemide) may provide greater diuresis and better 
  
safety profile compared with bolus injection. A meta-analysis of studies comparing continuous 
infusion vs.bolus injection of loop diuretics in acutely decompensated HF was performed by 
Salvador et al 
(42)
, urine output was greater in patients given continuous infusion. Electrolyte 
disturbances (hypokalemia, hypomagnesemia) were not significantly different between the two 
groups. There were fewer adverse effects (tinnitus and hearing loss) after continuous infusion 
compared with bolus injection. In addition, one study showed that the hospital duration of stay 
was significantly shortened  (by 3.1 days), one study showed lower cardiac mortality, and two 
studies showed lower all-cause mortality in patients treated with continuous infusion vs. bolus 
injection of furosemide. Therefore, most studies suggest a greater diuresis and better safety 
profile when loop diuretics are given as a continuous infusion. However evidence is insufficient 
to definitively recommend one method of administering loop diuretics, and further larger studies 
are needed. 
In addition to the mode of administration of loop diuretics, the addition of thiazide diuretics in 
combination with loop diuretics has been shown to improve efficacy and diuretic 
responsiveness in severe refractory HF 
(43, 44)
. Dormans and Gerlag 
(44)
 found that in 20 patients 
with New York Heart Association (NYHA) class III and IV HF, edema, and diuretic 
resistance, addition of hydrochlorothiazide to furosemide resulted in a mean body weight 
reduction   of 6.7 ±3.3 kg per patient. Mean daily urine volume increased and fractional 
sodium excretion increased significantly (p <.001 for both).  Due to potentially dangerous 
adverse effects, such as hypokalemia, metabolic alkalosis, and dehydration, careful monitoring 
of the patient is necessary if combination diuretics are used. 
 
  
CONSIDER RENAL-SPECIFIC THERAPIES 
RENAL DOSE DOPAMINE: 
The use of low-dose or “renal dose” dopamine, at doses <5 μg/kg/min has been proposed in the 
past to prevent or treat acute renal failure and  to  increase urine output in HF patients refractory 
to loop diuretics. Physiologically, low-dose dopamine increases renal blood flow and increases 
urine output by stimulating both dopaminergic (DA-1 and DA-2) and adrenergic (both α and β) 
receptors. Therefore, low-dose dopamine may affect renal blood flow by direct vasodilation 
(dopamine receptors), by increasing cardiac output (β receptors), or by increasing perfusion 
pressure via vasoconstriction (α receptors). At low doses (especially <2 μg/kg/min), 
dopaminergic receptor effects predominate, resulting in renal vasodilatation and increased renal 
blood flow. Dopamine also inhibits aldosterone release and inhibits sodium-potassium ATPase at 
the tubular epithelial cell level, resulting in increased sodium excretion and thereby diuresis 
(45 – 
49)
. Several early studies showed significantly increased natriuresis, diuresis, and improved renal 
function with use of low-dose dopamine 
(48, 50, 51)
. Other studies have also suggested a role for 
dobutamine, ibopamine (a dopamine congener), and fenoldopam in reducing  renal vascular 
resistance, increasing cardiac output, and increasing natriuresis, urine flow, and CrCl. However, 
these studies were largely small, underpowered, and nonrandomized. 
The overwhelming consensus among studies with more rigorous methodology is that there is 
no convincing scientific evidence of a beneficial effect with low-dose dopamine beyond a 
possible natriuretic diuresis 
(52)
. Furthermore, dopamine has significant potential side effects, 
including digital cyanosis and gangrene
 (53)
. Kellum and Decker 
(45)
 concluded that “the use of 
low-dose dopamine for the treatment or prevention of acute renal failure cannot be justified 
  
on the basis of available evidence and should be eliminated from routine clinical use.” 
Therefore, based on these studies, there is little if any role for renal dose dopamine in heart 
failure therapy in attempts to preserve renal function. 
 
NESIRITIDE AS RENAL PROTECTIVE THERAPY: 
Nesiritide (synthetic human B-type natriuretic peptide) is a potent vasodilator that has been used 
to rapidly reduce cardiac filling pressures and improve dyspnoea in patients with ADHF 
(54-57)
. 
Several early moderately sized controlled trials 
(57–61)
 suggested that nesiritide was safe in the 
short-term management of these patients. However, studies conflict on nesiritide’s effects on 
renal function, natriuresis, and diuresis. 
Recently, in a preliminary report from Owan et al.  
(62)
, use of standard dose nesiritide, despite 
lowering blood pressure, was associated with improved renal function indices at 24 hours. 
Furthermore, preliminary findings from a trial in which nesiritide was administered at a 
standard dose (0.01 μg/kg/min) without a bolus to patients undergoing cardiac surgery have 
been reported, and a marked reduction in the incidence of renal dysfunction was noted
(63)
. 
Thus, the role of nesiritide as a renal-protective and diuresis-promoting therapy in ADHF 
remains promising but requires further study. 
ULTRAFILTRATION: 
When traditional medical therapies fail or patients become resistant to diuretics, other therapeutic 
options must be undertaken to relieve volume overload. Ultrafiltration has been recognized as a 
  
viable treatment option by the Heart Failure Society of America and the ACC/AHA for 
diuretic-resistant HF (strength of evidence = C)
 (64)
. 
Ultrafiltration (UF) or slow continuous UF filters plasma water directly across a 
semipermeable membrane in response to a transmembrane pressure gradient, resulting in an 
ultrafiltrate that is isoosmotic compared with plasma water 
(65, 66)
. In contrast, hemodialysis 
involves the passage of solutes and water from the blood across a semipermeable membrane 
down a concentration gradient between the blood and dialysate via diffusion, allowing for 
changes in electrolytes and small solutes. Hemofiltration uses membranes with greatly 
increased hydraulic permeability, so that solute is removed by bulk flow 
(66, 67)
. In continuous  
venovenous  hemofiltration,   fluid and  medium-sized  solutes  are  removed by bulk  flow and  
solvent  drag  at  large volumes per hour, with replacement  fluids administered  to the  patient  
simultaneously. This allows for clearance of potentially toxic solutes, while maintaining stable 
hemodynamics. Continuous veno-venous hemodiafiltration is essentially continuous 
venovenous hemofiltration with the addition of dialysate on the other side of the 
semipermeable membrane, allowing diffusion of small solutes to occur simultaneously with 
continuous veno-venous hemofiltration. 
Ultrafiltration has been studied extensively and proven to be an effective treatment for patients 
with HF who are fluid overloaded and diuretic resistant, with fewer adverse effects than 
hemodialysis and peritoneal dialysis. UF promotes the resorption of systemic extravascular water 
and can effectively treat pulmonary edema in patients with HF. 
The radiographic score of lung water, exercise tolerance (peak oxygen consumption), dynamic 
lung compliance, ventilation, tidal volume, and deadspace/ tidal volume ratio at peak exercise 
  
improved significantly 
(68)
. In addition, there were improvements in neurohumoral responses 
(69)
. In contrast,  furosemide infusion at a dosage that achieved equivalent fluid removal 
produced clearing of the lungs, but this benefit was not sustained, and the dramatic 
improvements in lung function, exercise performance, and neurohumoral function observed 
with the UF treatment were not observed with diuretic administration titrated to produce a 
similar reduction  in right atrial pressure
(69, 70)
. These remarkable observations suggest that this 
form of therapy may have unique benefits, but these elegant studies have not been repeated in 
patients with ADHF and marked volume overload. 
Recently, a peripherally inserted UF device manufactured by HF Solutions (Aquadex, System 
100) was approved by the FDA for therapy in HF. This device allows UF to  be performed at 
very low flows (40 mL/min) using only a peripheral intravenous  catheter  and a midline 
catheter in an antecubital vein, with only 33– 40 mL of extracorporeal blood at any given 
time. This simple machine is designed for use by non nephrologists and nurses, avoiding the 
need for intensive care or dialysis units. 
Importantly, UF was shown to remove more sodium and less potassium than diuretics for an 
equivalent amount of volume reduction 
(71)
. This critical difference may promote more 
sustained volume reduction and offer the potential for improved long-term outcomes with UF 
compared with diuretics. However, the expense and complexity of treatment limit the 
potential use of UF as a first-line strategy in all patients with ADHF. Whether rescue therapy 
with UF in patients with established cardiorenal syndrome will prove superior to standard care 
remains to be established. 
 
  
INVESTIGATIONAL THERAPIES FOR CARDIORENAL SYNDROME 
HYPERTONIC SALINE PLUS FUROSEMIDE: 
Paterna et al 
(72)
 described success in treating patients with refractory HF with the combination 
of high-dose furosemide and small-volume hypertonic saline solution. A total of 94 patients 
with refractory HF were randomized to receive either high-dose intravenous furosemide (500 –
1000 mg) plus hypertonic saline solution twice a day in 30 mins or intravenous bolus 
furosemide (500 –1000 mg) twice a day, for 4–6 days. Significant increases in daily diuresis and 
natriuresis, as well as improvements in B-type natriuretic peptide and bioelectrical impedance 
measurements, were observed in the furosemide plus hypertonic saline solution group. The 
hypertonic saline solution group also showed a significant reduction in hospitalization time and 
readmission rate. 
Potential mechanisms of increased sodium load in the therapy of HF may relate to an acute 
osmotic effect of hypertonic saline to increase mobilization of extravascular fluid into the 
central circulation and renal circulation. Increases in renal blood flow may facilitate diuretic 
responsiveness. In addition, direct intra tubular effects of sodium flooding may overwhelm the 
rebound sodium retention seen in diuretic therapy, thus reducing the “braking phenomenon” 
discussed previously. Furthermore, neurohormone levels may have been suppressed by 
hypertonic saline. The increased intravascular volume and greater distal tubule sodium delivery 
may inhibit the RAAS, causing reductions in aldosterone, angiotensin II, and vasopressin (or 
antidiuretic hormone) release despite a temporary increase in serum osmolarity. There  may  
also  be  a small contribution  of increased intravascular volume causing inhibition  of ADH  
release via volume/ baroreceptors, leading to reduced free water resorption  via aquaporin  
  
channels in  the  collecting  tubules  of the  kidney 
(74)
. This novel strategy has yet to be tested 
by other groups. 
VASOPRESSIN ANTAGONISTS IN HEART FAILURE THERAPY: 
Vasopressin antagonists represent another promising class of therapeutics that may improve 
aquaresis and hyponatremia in patients with chronic HF. Vasopressin, also known as arginine 
vasopressin or antidiuretic hormone, is a cyclic hexapeptide produced in the hypothalamus and 
released from secretory granules in the posterior pituitary lobe in response to hyperosmolality, 
volume depletion, angiotensin II, and sympathetic stimulation.   
Vasopressin causes vasoconstriction and renal water resorption via the vasopressin receptor 
subtypes V1a (vascular), V2 (renal), and V3 (pituitary) receptors 
(75, 76)
. V1a receptors, found in 
vascular smooth muscle cells and the kidney, mediate vasoconstriction and prostaglandin 
production at supra-physiologic concentrations of vasopressin 
(77)
. V2 receptors,  found  in  the  
renal collecting tubules (principal cells), mediate renal water resorption via insertion of 
aquaporin 2 channels into the luminal membranes  and also release of von Willebrand  factor  
and  factor  VIII from  the vascular  endothelium. V3 receptors, found in the pituitary gland, 
are responsible for stimulating adrenocorticotropic hormone secretion by pituitary 
corticotropes. 
In HF, vasopressin levels are elevated due to signaling of the carotid sinus baroreceptors 
functioning as volume receptors in the setting of decreased effective arterial blood volume 
from low cardiac output. When systemic blood pressure drops sufficiently, as in advanced 
HF, antidiuretic hormone secretion markedly increases to levels that far exceed those induced 
  
by changes in plasma osmolality. In addition, the volume depletion can prevent the inhibition 
of antidiuretic hormone release normally induced by a decrease in plasma osmolality, which 
contributes   to the development of hyponatremia in HF. 
Antagonism of the V1a and V2 receptors may be beneficial in HF patients 
(77–80)
. Antagonism 
of V1a receptors increases cardiac output, reduces total peripheral vascular resistance, reduces 
mean arterial blood pressure, and inhibits vasopressin-mediated cardiomyocyte hypertrophy 
(77)
. Antagonism of V2 receptors results in aquaresis, causing increased serum sodium 
concentration and reduced cardiac preload 
(77)
. In HF, two vasopressin antagonists have shown 
promise in early clinical trials:                       
1) conivaptan (YM-087), an oral or intravenous V1a/V2-receptor antagonist; and          
2) tolvaptan (OPC-41061), an  oral  specific V2-receptor antagonist. 
Conivaptan reduced preload and increased urine output and serum sodium levels. Currently 
o n l y  the intravenous formulation of conivaptan has been developed and approved and it is 
only approved for treatment of patients with euvolemic hyponatremia. 
Tolvaptan, an oral V2-receptor antagonist, has been shown to induce aquaresis in humans
(81, 82 
)
.  Tolvaptan significantly decreased  body weight,  increased  urine volume, increased net 
fluid loss, decreased urine osmolality, increased mean total 24-hr urinary sodium excretion, 
increased serum sodium, and improved edema when combined with standard diuretic regime. 
Its effect was observed primarily on the first day. After 24 hrs, patients treated with tolvaptan 
had a significant reduction in body weight compared with those administered placebo; this 
effect was not dose dependent. 
  
The efficacy of Vasopressin Antagonism in heart failure Study with Tolvaptan (EVEREST) trial 
is an ongoing international, multicenter study designed to evaluate the long-term e f f i c a c y  
and safety of oral once-daily tolvaptan in patients hospitalized with worsening HF
(83)
. 
 
ADENOSINE ANTAGONISTS IN HEART FAILURE THERAPY:  
Another promising new class of therapeutic agents is the A1 adenosine receptor antagonists. 
Plasma adenosine levels are elevated in patients with HF, with increasing levels as the 
severity of disease increases 
(83)
. TGF promotes release of adenosine, and adenosine binding to 
A1 receptors causes vasoconstriction of the afferent arteriole, decreased renal blood flow and 
GFR, and enhanced sodium resorption by the proximal tubule. Antagonism of A1 adenosine 
receptors has the potential to improve renal function and overcome DR in patients with HF by 
disrupting the TGF loop 
(84)
.  
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MATERIALS AND METHODS OF THE STUDY 
PATIENT SELECTION 
The study group comprised of 50 heart failure patients. The patient subgroup was drawn from a 
consecutive series of 78 heart failure patients admitted in the Department of Medicine, Stanley 
Medical College and Government Stanley hospital, during the period of 4 months from March 1
st
 
2010 to June 30
th
 2010. 
For the study purpose clinical diagnosis of heart failure was confirmed with echocardiographic 
evaluation.  
 
INCLUSION CRITERIA 
All patients admitted with cardiac failure of any etiology with a duration of hospital stay more 
than 24 hrs with or without cardiorenal dysfunction.  
 
EXCLUSION CRITERIA 
1. Patients with documented chronic kidney disease including renal artery stenosis. 
2. Patients with Diabetic nephropathy (proteinuria >300mg/24 hrs). 
3. Patients with history of NSAID abuse. 
4. Serum creatinine >5 mg/dL 
5. Patients not satisfying above criteria( hospital stay <24 hrs) 
 
  
PATIENT EVALUATION 
Patients included in the study were thoroughly evaluated clinically, biochemically, 
ultrasonographically and echocardiographically. 
Patients name, age, sex, marital and socioeconomic status were noted as part of positive data. 
Presenting complaints of breathlessness on exertion(NYHA class), pedal edema, abdominal 
distension, chest pain, palpitation and  fatigue were analyzed in detail, evidence of coronary 
artery disease, rheumatic heart disease, hypertension, diabetes mellitus, dyslipidemia, sedentary 
life style, obesity, current active smoking, current alcohol abuse and family history of risk factors 
including cardiomyopathy were obtained.  
A clinical examination pertaining to heart failure was performed including a relevant general 
examination, vital signs and cardiovascular system. Other systems of respiratory, gastrointestinal 
and nervous system were examined and relevant details were noted. 
The clinical diagnosis of heart failure was made based on ACC/AHA guidelines consisting of the 
pyramid approach to heart failure stages. Obesity was defined based on BMI, dyslipidemia on 
serum total cholesterol, smoking by Smoking Index and alcohol use >100ml/day for > 3 months. 
Biochemical investigations done in this study included admission blood glucose, fasting and post 
prandial blood glucose, admission blood urea and serum creatinine, myocardial enzyme assay for 
acute coronary syndromes, fasting lipid profile, thyroid function test and repeat serum creatinine 
periodically (24 hrs, 48 hrs and on discharge). Chest roentgenogram PA view and ultrasonogram 
were also done.   
  
Patients with active urinary sediments on microscopic examination were excluded from study. 24 
hours Urine protein was obtained from each of these patients and those patients with proteinuria 
more than 300mg/24 hrs were also excluded from the study. 
Creatinine clearance was estimated using Cockroft- Gault formula. 
Echocardiography was done for all these patients. Both 2D and color Doppler echocardiography 
was done by a single experienced cardiologist. Left ventricular systolic performance was 
quantified as the LV ejection fraction. The operational definition of systolic dysfunction for 
study purpose is an ejection fraction of less than 50%. The left ventricular diastolic performance 
was quantified by Doppler and graded from I to III.  
All clinical biochemical and echocardiographic variables were duly entered in a proforma 
especially designed for the study. 
PATIENT  FOLLOW UP 
All the 50 patients included in the study were followed up till the time of discharge, and were 
followed for a minimum period of 2 months. All details regarding functional improvement, 
worsening symptoms, duration of hospital stay and in hospital death were carefully recorded. 
Information about deceased patients were obtained from family members. Particular attention 
was given to the circumstances of each death. 
STUDY DESIGN 
This study is a prospective cross sectional observational study. 
 
  
 
 
 
OBSERVATIONS AND 
STATISTICAL ANALYSIS 
 
 
 
  
OBSERVATIONS AND STATISTICAL ANALYSIS 
 
The study population was subgrouped into heart failure alone group and heart failure with 
cardiorenal syndrome (CRS) group (defined by serum creatinine ≥ 1.4 mg/dL or creatinine 
clearance <60 ml/min or rise in serum creatinine >25% (>0.3 mg/dL) of baseline on attempted 
diuresis).  
STATISTICAL METHODS 
All continuous variables were assumed to be normally distributed and are reported as arithmetic 
mean with their standard deviation. The 95% confidence intervals are also reported where 
clinically applicable. The Fisher’s Exact test was used to compare and analyze the data. The null 
hypothesis was rejected at the 95% confidence interval, considering a probability value of   P < 
0.05 as statistically significant.  
Statistical analysis was done using IBM SPSS® Statistics Version 19. 
 
 
 
 
 
 
  
 
 
 
RESULTS 
 
 
 
 
  
RESULTS 
50 patients who were admitted in medical wards with heart failure who satisfied the inclusion 
and exclusion criteria were enrolled in this study. Out of the 50 patients, 32 were males and 18 
were females. The youngest among them was 16 yrs and oldest being 72 years of age.  
TABLE -1 
SEXWISE DISTRIBUTION OF PATIENTS IN THE STUDY 
SEX NUMBER OF PATIENTS PERCENTAGE 
MALES 32 64% 
FEMALES 18 36% 
 
18 patients out of 50 satisfied criteria for diagnosis of heart failure with Cardiorenal Syndrome 
(Serum creatinine >1.3 mg% at admission and creatinine clearance <60 ml/kg/1.73m² OR a rise 
in serum creatinine >25% on attempted diuresis). Further analysis were carried out among this 
subgroup labeling them as CRS group and the remaining 32 patients as Heart Failure Alone 
group.  
TABLE – 2 SEXWISE DISTRIBUTION OF PATIENTS IN THE STUDY GROUPS 
HEART FAILURE ALONE  CARDIORENAL SYNDROME 
MALE 20 62.5% MALE 12 66.66% 
FEMALE 12 37.5% FEMALE 6 33.33% 
TOTAL 32 100% TOTAL 18 100% 
 
  
 
 
 
Sex Distribution in Study Groups 
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ETIOLOGY OF HEART FAILURE 
 
Both groups were comparable as far as the etiology of heart failure was concerned. Half of the 
patients were ischemic heart disease and another one-fourth were having rheumatic heart disease 
in both groups. 
 
TABLE – 3 
ETIOLOGY OF HEART FAILURE 
 
 
 
 
 
 
 
 
 
 
ETIOLOGY HEART FAILURE ALONE CRS GROUP 
RHD 8 4 
ACS 5 2 
IHD 13 9 
HT/LVF 3 0 
Congenital Heart Disease 2 1 
Cor Pulmonale 1 1 
Alcoholic Cardiomyopathy 0 1 
Total 32 18 
  
ETIOLOGY OF HEART FAILURE 
 
 
AGE WISE DISTRIBUTION OF PATIENTS IN STUDY GROUP
 
4
22%
2
11%
9
50%
1
5%
1
6%
1
6%
8
25%
5
16%
13
41%
3
9%
2
6%
1
3% RHD
ACS
IHD
HT/LVF
CHD
Cor Pulmonale
Alcoholic CMP
0
1
2
3
4
5
6
7
8
9
10
11-20 yrs 21-30 yrs 31-40 yrs 41-50 yrs 51-60 yrs 61-70 yrs >70 yrs
4
1
3
8
10
5
1
0
1
2
6
7
2
0
Male
Female
CRS Group 
HF Alone 
Group 
  
TABLE - 4 
AGE WISE DISTRIBUTION OF PATIENTS IN STUDY GROUP 
Age Group Male Female Total 
11-20 years 4 0 4 
21-30 years 1 1 2 
31-40 years 3 2 5 
41-50 years 8 6 14 
51-60 years 10 7 17 
61-70 years 5 2 7 
71-80 years 1 0 1 
 
 
FREQUENCY DISTRIBUTION ACCORDING TO AGE GROUPS 
When the frequency distribution of two groups were plotted against age group intervals the CRS 
group had a skewing towards 50-70 years (negative skewing) and Heart failure alone group 
positively skewed in 40-60 yrs (see chart next page). 
Median age of CRS group is 58 years (Minimum 16 yrs and maximum 72 yrs) and that of heart 
failure alone group 48 yrs(Minimum 16 yrs and maximum 65 yrs), a difference of 10 years with 
a two-tailed p value of 0.0140, considered statistically significant. 
 
  
FREQUENCY DISTRIBUTION ACCORDING TO AGE GROUPS 
 
 
Out of 50 patients majority belonged to NYHA Class III and Class IV (24 in each group, 96%), 
only 4 % patients were admitted with NYHA Class II symptoms. 
The BMI of both groups were identical ( Mean BMI of heart failure alone group 22.97 kg/m² and 
that of cardiorenal syndrome group 23.33 kg/m² and the difference was statistically not 
significant (p value 0.6896). 
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ANALYSIS OF RISK FACTORS 
Univariate analysis of risk factors for the development cardiorenal syndrome in heart failure by 
Fisher’s Exact Test using 2x2 contingency tables showed statistically significant risk associated 
with Diabetes Mellitus ( p=0.0176), Smoking (p=0.0352), and Left ventricular Diastolic 
dysfunction (p<0.0001, extremely significant). See Table – 5 & 6.  
However Systemic Hypertension, Dyslipidemia, Alcoholism and Systolic left ventricular 
dysfunction (Ejection fraction <50%) failed to show any statistically significant difference. See 
table 5 
 
 
SERUM CRETININE AND CREATININE CLEARANCE 
Mean serum creatinine at the time of admission in the heart failure alone group is 0.78 mg% 
(with 95% CI between 0.70-0.84) where as in the CRS group it is 1.91 mg% (with 95% CI 
between 1.52-2.30). The two-tailed P value is < 0.0001, considered extremely significant. 
Similar was the results with creatinine clearance, mean in HF group of 100.81 (CI 90-111) and 
40.01 in CRS group (CI 32.54-47.48), with p <0.0001. 
 
 
 
  
TABLE – 5 
ANALYSIS OF RISK FACTORS 
 
RISK FACTOR 
CRS 
HF 
ALONE 
P Value 
(Fisher’s Exact Test) 
Relative 
Risk 
Diabetes 
Mellitus 
Present 13 11 
0.0176 2.81 
Absent 5 21 
Hypertension 
Present 12 15 
0.2410 
Not 
significant Absent 6 17 
Dyslipidemia 
Present 11 18 
0.7742 
Not 
significant Absent 7 14 
Smoking 
Present 11 9 
0.0352 2.36 
Absent 7 23 
Alcoholism 
Present 9 14 
0.7709 
Not 
significant Absent 9 18 
Systolic 
Dysfunction 
Present 11 14 
0.3772 
Not 
significant Absent 7 18 
Diastolic 
Dysfunction 
Present 17 12 
<0.0001 12.310 
Absent 1 20 
 
 
 
  
TABLE – 6 
ANALYSIS OF RISK FACTORS 
 
 
 
 
Parameter 
 
Heart Failure 
 
CRS Group 
 
P value 
 
Blood Sugar 
Mean 114.34 104.77  
    0.438 Standard Deviation 47.583 27.32 
95% CI 97.19 -131.50 91.19 – 118.37 
 
Total cholesterol 
Mean 208.44 211.22  
    0.789 Standard Deviation 45.67 46.04 
95% CI 191.97 -224.91 198.12 -224.32 
 
Cardiothoracic 
Ratio 
Mean 0.559 0.560       
     0.904 Standard Deviation 0.033 0.035 
95% CI 0.55 – 0.57  0.55 -0.57 
 
Ejection fraction 
Mean 50.81% 41.17%     0.0001 
(significant) Standard Deviation 6.30 10.08 
95% CI 48.54 – 53.08 36.15 - 46.18 
  
TABLE – 7 
SERUM CREATININE AND CREATININE CLEARANCE 
SERUM CREATININE ON ADMISSION 
Study Group 
Sample 
size 
Mean 
Standard 
Deviation 
Maximum Minimum T value P value 
Heart failure 
Alone 
32 0.78 0.19 1.2 0.6 
7.839 <0.0001 
Cardiorenal 
syndrome 
18 1.91 0.78 4.2 1.4 
 
 
CREATININE CLEARANCE ON ADMISSION 
Study Group 
Sample 
size 
Mean 
Standard 
Deviation 
Maximum Minimum T value P value 
Heart failure 
Alone 
32 100.82 28.52 202.0 63.20 
8.388 <0.0001 
Cardiorenal 
syndrome 
18 40.01 15.02 58.10 12.30 
 
 
  
Thyroid function tests revealed 2 hypothyroid patients from the CRS group and one from heart 
failure alone group. 
MORBIDITY AND MORTALITY 
Morbidity was assessed quantitatively in terms of duration of hospital stay in addition to the 
functional improvement. The mean duration of hospital stay was 6.78 days in heart failure group 
compared to 11.06 days for CRS group, the average difference of 3.28 days (p<0.000, 
statistically significant). 
3 out of 18 CRS patients died before discharge( In hospital mortality of 16.66 %) whereas only 2 
out of 32 in the heart failure alone group died within hospital( mortality 6.25%). 11 of the 18 
CRS group patients had further renal impairment within 24 hrs of initiating diuretic therapy 
(61%).  
CRS group had a prolonged hospital stay of 3.28 days as compared to heart failure alone group. 
FOLLOW UP AND OUTCOME 
28% of CRS group patients(5 out of 18) died during hospital stay or within the 2 months follow 
up( 3 in-hospital, 2 during follow up ) considerably high as against 9.38% in Heart Failure alone 
group, approximately 3 fold increased mortality. 
Only 16% completely recovered in CRS group as against 60% in others, 54% had persistent 
symptoms or improved only partially. 
 
 
  
OUTCOME 
Group 
CRS HF Alone 
 Complete Recovery 3 19 
Partial Recovery 5 10 
Persistent Symptoms 5 0 
Death 5 3 
 Total 18 32 
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DISCUSSION 
 
 
 
 
  
DISCUSSION 
In ambulatory heart failure patients, the presence of concomitant
 
renal dysfunction is consistently 
a strong risk factor for morbidity and mortality. This risk becomes evident
 
even at serum 
creatinine levels ≥1.4 mg/dL and estimated creatinine clearance values ≤60 mL/min. 
Furthermore,
 
renal function is at least as powerful an adverse prognostic
 
factor as most clinical 
variables, including ejection fraction
 
and New York Heart Association functional class. Although 
renal
 
dysfunction predicts all-cause mortality, it is most predictive
 
of death from progressive 
heart failure, which suggests that
 
it is a manifestation of and/or exacerbating factor for 
left
 
ventricular dysfunction. 
This study conducted at Stanley Medical College reaffirms the progressive nature of cardiorenal 
syndrome and its adverse outcome even in a small number of subjects. The studied population 
had a prevalence of 36% of Cardiorenal Syndrome in acute and chronic heart failure which is 
considered comparable to other studies. The prime focus of the study was in looking at the 
disease from functional aspect of the heart (i.e. Type I and Type II CRS). The more recent 
updates from across the world has a broader outlook and focuses Reno-Cardiac dysfunction also.  
An attempt was made at assessing the predictors of morbidity and mortality, and Diabetes, 
Advancing age, 2 or more previous hospitalizations, a history of cardiorenal dysfunction, 
diastolic dysfunction, and a smoking index  of >20 were independently associated and the 
association was extremely significant.  
Surprisingly a history of hypertension could not predict cardiorenal syndrome by itself, likely to 
be due to the “Iceberg phenomenon” of non communicable disease. The fact that more than 90% 
of them had diastolic dysfunction of some degree during echo evaluation points the same. This 
  
again throws light towards heightened pulmonary capillary wedge pressure (PCWP) and 
systemic venous congestion recently proposed as contributors for renal dysfunction in heart 
failure. 
In the setting of hospitalization for decompensated heart failure,
 
worsening renal function is even 
more important than baseline
 
renal function for predicting adverse outcomes. This needs more 
randomized controlled trials and evaluation because an early identification of susceptible patient 
may benefit goal directed therapy. 
Unfortunately, we have no evidence from clinical heart failure
 
trials on which to base our therapy 
for patients with significant
 
renal dysfunction, largely because these studies predominantly 
recruited populations with relatively preserved renal function.
 
As a result, treatment is largely 
empirical. Inhibitors of the
 
renin-angiotensin-aldosterone system are the cornerstone of
 
our 
management of patients with left ventricular systolic dysfunction,
 
and they also prevent 
progressive renal dysfunction in diabetic
 
nephropathy and other forms of chronic kidney disease. 
Unfortunately,
 
in the presence of underlying renal disease, use of angiotensin-converting
 
enzyme 
(ACE) inhibitors and other renin-angiotensin-aldosterone
 
inhibitors may be associated with 
elevations in creatinine,
 
thereby creating a therapeutic dilemma. Although physicians
 
frequently 
avoid or discontinue these medications for fear of
 
exacerbating renal function,
 
the rise in 
creatinine levels
 
after the initiation of an ACE inhibitor actually may identify
 
a subgroup of 
patients who will achieve the greatest benefit
 
from their use.
 
Furthermore, discontinuation of 
ACE inhibitors
 
because of renal dysfunction identified a patient group with
 
a high mortality risk 
during recent trials. Therefore, a sensible approach is to continue these agents despite
 
a rise in 
creatinine, as long as renal dysfunction does not
 
steadily deteriorate and severe hyperkalemia 
does not develop.
 
Consider the diagnosis of renal artery stenosis in patients
 
who are extremely 
  
intolerant to ACE inhibitors. In patients who present with the combination of worsening
 
renal 
function, volume overload, and diuretic refractoriness,
 
the management of cardiorenal 
dysfunction is extremely challenging. 
In short the study was valuable in identifying a subgroup of people among heart failure patients 
who had independent predictors of clinical deterioration, worsening renal function, increased 
morbidity and mortality who need special and intensive care and treatment strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
  
STUDY LIMITATIONS 
This study results are limited by a number of important factors. First and foremost is the sample 
size. For a disease which has a very high prevalence, it may be essentially difficult to draw 
conclusions from a small group of population especially considering the nature of the study 
centre (tertiary care). Population behavior is to seek health care only when the functional 
limitation becomes severe enough to disturb day to day activities. So the estimated prevalence 
may be an exaggerated one. 
Second factor is the definition of cardiorenal syndrome. Several of the recent studies have 
accepted the criteria used in our study. There are difference of opinion in defining worsening 
renal function based on serum creatinine (Cr≥1.4 mg/dL OR Cr≥ 1.3 mg/dL, and also rise in 
creatinine on attempted diuresis,  ≥0.3 mg% or >0.3 mg%) and may influence the prevalence. 
The study patients received treatment from different physicians and the treatment protocol was 
individualized. So the outcome difference would have had some impact due to these factors. 
The study was aimed mainly at looking the renal dysfunction secondary to heart failure (type 1 
and type 2), the recent concept of cardiorenal syndrome has a broader view including            
Reno-cardiac syndromes. So the study underestimated the prevalence and actual prevalence may 
rise even to 50% or more.  
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CONCLUSION 
The cardiorenal syndrome often heralds the transition of heart failure to an end-stage, 
preterminal (stage D) heart failure.  
The conclusions of the study are the following. 
1. The prevalence of Cardiorenal syndrome in heart failure is quite high (36%). 
2. History of 2 or more previous hospitalizations and advancing age in patients with heart 
failure predispose them in developing cardiorenal syndrome. Patients who developed 
cardiorenal syndrome were older by a mean of 10 years (p value = 0.0140). 
3. The relative risk of cardiorenal dysfunction is high with Smoking, Diabetes Mellitus and 
Left ventricular Diastolic Dysfunction. 
4. In addition to prolonged hospitalization (by 3.28 days) and slower recovery, the 
development of cardiorenal syndrome is an independent predictor of frequent 
readmissions. The in-hospital and 2 month follow up mortality is 3 times higher in 
cardiorenal syndrome when compared to heart failure alone group. 
Under-treatment of the cardiorenal syndrome may have lethal consequences at an 
individual level and huge potential adverse consequences at a public health level.  The 
depth of knowledge and complexity of care necessary to offer best therapy to these patients 
demands a multidisciplinary approach, combining the expertise of cardiology, nephrology, 
and critical care.  
  
  
Further research is needed to clarify its pathophysiology and adequate methods of 
management. Till then individualization of each patient with judicious use of drugs is the 
best line of management.  
Emerging therapies bring hope for better outcomes in these challenging patients.  
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A STUDY OF CHARACTERISTICS AND OUTCOME OF CARDIO RENAL 
SYNDROME IN HEART FAILURE 
PROFORMA 
1. Name : 
2. Age : 
3. Sex : 
4. Educational status : 
5. Occupation : 
6. Address : 
7. Telephone No: 
8. Height in cms : 
9. Weight in kgs : 
10. BMI(kg/m2 ) 
11. Clinical presentation on admission : 
12. Duration of Onset of symtoms : 
13.  No of previous hospitalisations : 
14. NYHA Functional Class: 
15. Hypertension : Y / N 
How  many yrs:   Treatment: 
16.  Diabetes :       Y / N 
How many yrs: Type    : Treatment: 
17. Hyperlipidemia :  Y/N  Treatment: 
  
18. Alcohol : Y /N  
19. Smoking: Y / N 
20. Tobacco chewing: Y / N 
21. Sedentary habits: 
22.  Menstrual H/O:  
a. Premenopausal / Postmenopausal/ Yrs since menopause: 
23. General examination 
a. Consciousness :                          
b. Orientation :            
c. Anemia : 
d. Clubbing : 
e. Icterus :                  
f. Pedal edema :              
g. JVP : 
h. Markers of Hypercholesterolemia : 
i. PR : Rate         /min 
i. Regular/irregular 
ii. Vessel wall thickening 
iii. Renal bruit 
j. BP :                mmHg 
k. RR :          / min 
l. Temp: 
 
  
24. CVS:  
Apical Impulse: 
Heart Sounds: 
Added sounds 
Murmurs:  
25. RS : 
Air entry: 
Adventitious sounds: 
26. P /A : 
 
Etiology of Cardiac failure  : 
Duration of hospital stay : 
Outcome : 
Follow up : 
Readmissions if any : 
 
  
INVESTIGATIONS : 
1.CBC: TC                    DC                     ESR 
                Hb                    PCV                   Platelets 
 2.RFT :  
 Urea    
 Creatinine 
 Creatinine clearance  
 Electrolytes Na 
   K 
3. FBS   
4. PPBS 
5. Total cholesterol : 
6.Urine R /E : Albumin : Sugar:  Deposits:  
7. ECG : 
8. CXR : Cardiothoracic ratio: 
9.ECHO:   LVEDD 
  Systolic Dys:   Diastolic Dysfunction: 
  Peri. Effusion:   EF: 
10. Ultrasound Abdomen 
 LK   RK 
 CMD   PCS Ascites 
11.Thyroid Function Tests(T3, T4, TSH) 
Day 1 Day2 Day 3 Day Disch 2 months 
     
     
     
     
     
A STUDY OF CHARACTERISTICS AND OUTCOME OF CARDIO RENAL SYNDROME IN HEART FAILURE
MASTER CHART
No Ag Sx H W BMI PH NY HTN DM DL Sm Alc HS Hb BU CrD1 CrD2 CrDd CrCD1 CH CTR EF SD DD Re O
1 65 M 170 70 24.22 3 4 N Y Y Y Y 10 11 60 3 4.4 2.1 24.3 255 0.6 48 Y 2 2 2
2 48 M 160 68 26.56 4 4 Y Y Y Y Y 7 7 40 1.8 1.5 1 48.3 254 0.5 50 N 1 0 1
3 16 M 150 48 21.33 0 3 N N N Y N 8 10 34 1.4 0.7 0.7 59.0 154 0.55 54 Y 0 0 1
4 62 F 156 65 26.71 4 4 Y Y Y N N 21 11 49 1.5 2.5 2.5 46.9 290 0.6 28 Y 2 4
5 45 M 165 58 21.30 2 3 N N N N N 7 8.5 60 2.1 1.5 1.4 36.4 160 0.62 49 N 1 1 2
6 50 M 157 50 20.28 2 4 N N N Y N 21 8 65 1.5 1.8 1.4 41.7 150 0.6 39 Y 2 2 3
7 48 M 160 65 25.39 2 3 Y Y N Y Y 7 10 45 1 1.5 1.4 83.1 210 0.5 50 N 1 0 1
8 70 F 155 53 22.06 4 4 Y Y Y N N 6 10 100 4.2 3.1 5 12.3 260 0.55 24 Y 1 4
9 60 F 156 52 21.37 2 3 Y Y Y N N 12 11 34 1.4 1.8 1.3 41.3 220 0.53 42 Y 2 1 2
10 53 M 160 50 19.53 1 3 Y Y Y Y Y 15 12 35 1.5 2.1 1.8 40.3 287 0.6 40 Y 1 1 3
11 38 F 152 48 20.78 3 4 N N N N N 13 10 56 3.1 3.7 4 21.9 165 0.52 30 Y 1 4
12 68 M 150 65 28.89 3 3 Y Y Y Y Y 11 13 48 1.5 1.7 1.6 43.3 286 0.55 30 N 2 1 3
13 72 M 160 60 23.44 2 3 Y Y Y Y Y 11 10 52 1.7 1.5 1.4 33.3 190 0.57 38 Y 1 2 3
14 60 F 160 60 23.44 3 4 Y N N N N 10 12 64 2 1.9 3.2 33.3 172 0.55 26 N 2 2 4
15 54 M 162 62 23.62 0 3 Y Y Y Y Y 8 12 36 1.8 1.7 1.4 41.1 235 0.51 47 N 1 0 2
16 70 M 160 58 22.66 2 4 Y Y Y Y Y 12 11 35 1.5 1.6 1.6 37.6 197 0.59 50 N 1 1 3
A STUDY OF CHARACTERISTICS AND OUTCOME OF CARDIO RENAL SYNDROME IN HEART FAILURE
MASTER CHART
No Ag Sx H W BMI PH NY HTN DM DL Sm Alc HS Hb BU CrD1 CrD2 CrDd CrCD1 CH CTR EF SD DD Re O
17 60 F 154 62 26.14 2 4 Y Y N N N 10 10 60 2 3.2 3.6 34.4 186 0.59 40 Y 2 1 4
18 56 M 150 50 22.22 1 3 N Y Y Y Y 10 10.8 47 1.4 1.8 1.3 41.7 220 0.58 56 Y 1 1 2
19 40 F 160 55 21.48 2 4 N N N N N 3 10.8 62 1.2 1 0.8 63.7 160 0.5 52 Y 0 0 1
20 60 M 160 60 23.44 0 3 N N Y N Y 5 11 51 1 0.8 0.7 66.7 210 0.5 58 N 0 1 1
21 46 M 155 62 25.81 2 3 N N N Y Y 6 11.6 35 0.8 0.7 0.7 101.2 170 0.55 50 N 0 1 1
22 60 M 158 60 24.03 1 4 N N Y N Y 6 11 51 0.8 0.7 0.9 83.3 220 0.6 50 N 0 0 2
23 56 M 160 65 25.39 1 4 N N N Y Y 7 11.7 31 1.2 0.9 86 63.2 178 0.55 58 Y 0 1 1
24 16 M 150 50 22.22 1 4 Y N Y N Y 5 10.2 18 0.6 0.8 0.7 143.5 226 0.52 43 N 1 0 1
25 61 M 165 70 25.71 0 3 Y Y Y Y Y 6 13 19 0.7 0.8 0.8 109.7 262 0.6 55 Y 0 1 2
26 38 M 162 62 23.62 2 4 N N N N Y 8 12.5 22 0.8 0.7 0.8 109.8 172 0.6 47 N 1 0 1
27 55 M 170 60 20.76 1 3 Y Y Y Y Y 6 10.6 32 0.7 0.6 0.6 101.2 285 0.55 49 N 2 0 2
28 52 F 160 60 23.44 1 4 Y N Y N N 4 9.1 38 0.6 0.6 0.7 122.2 213 0.6 56 N 0 0 2
29 47 M 150 50 22.22 1 4 Y Y Y Y Y 6 8.2 30 0.6 1 0.8 107.6 210 0.53 54 Y 0 1 4
30 40 M 155 62 25.81 2 3 Y N Y N N 7 7.2 40 0.7 0.6 0.8 123.0 210 0.55 52 Y 0 1 1
31 32 F 152 45 19.48 0 3 N N N N N 7 8.5 40 0.8 0.7 0.8 84.4 160 0.54 54 N 0 1 1
32 45 F 160 64 25.00 1 2 Y N N N N 6 9 38 0.9 0.8 0.9 93.8 165 0.58 55 Y 0 1 2
33 55 M 155 60 24.97 0 4 Y Y Y Y Y 7 8 25 1 1 1.2 70.8 222 0.6 48 Y 2 1 1
A STUDY OF CHARACTERISTICS AND OUTCOME OF CARDIO RENAL SYNDROME IN HEART FAILURE
MASTER CHART
No Ag Sx Ht W BMI PH NY HTN DM DL Sm Alc HS Hb BU CrD1 CrD2 CrDd CrCD1 CH CTR EF SD DD Re O
34 21 M 156 45 18.49 1 3 N N N N N 7 11 28 1.1 1.2 0.8 67.6 145 0.55 54 N 0 1 1
35 48 F 160 65 25.39 1 4 N N Y N N 5 10.8 32 0.7 0.6 0.8 118.7 250 0.5 58 N 0 1 1
36 54 M 155 42 17.48 1 4 Y N Y N Y 10 10 40 0.7 0.8 0.7 71.7 210 0.6 48 N 0 1 2
37 48 F 160 50 19.53 2 3 N Y N N N 14 12 45 0.6 0.6 0.8 106.5 170 0.6 30 Y 1 4
38 39 M 150 68 30.22 0 3 Y N Y N N 8 14 31 1.1 1.2 1 86.7 300 0.55 50 Y 1 1 1
39 18 M 154 50 21.08 2 2 N N N N N 6 10 40 1 1 1.2 84.7 159 0.54 55 N 0 0 2
40 45 M 160 55 21.48 0 4 N Y N N N 7 15 45 0.7 0.7 0.8 103.7 190 0.55 58 N 0 0 1
41 30 F 155 53 22.06 1 3 N N N N N 7 14 38 0.6 0.8 0.8 135.0 176 0.54 52 N 0 0 1
42 65 M 158 60 24.03 1 3 Y Y Y Y Y 6 7 41 0.6 0.7 0.7 104.2 224 0.58 50 Y 2 1 2
43 55 F 160 55 21.48 1 3 Y N Y N N 8 10 32 0.7 0.7 0.6 92.8 234 0.6 48 Y 2 0 2
44 17 M 156 48 19.72 1 3 N N N N N 6 12 22 0.6 0.8 0.8 136.7 165 0.55 50 N 0 0 1
45 48 F 150 50 22.22 0 4 Y Y Y N N 8 10 30 0.6 0.6 0.6 106.5 221 0.6 55 Y 1 4
46 55 F 160 60 23.44 1 4 N N Y N N 6 12 41 0.9 0.9 0.7 78.7 288 0.55 56 N 1 0 1
47 55 M 160 55 21.48 2 4 Y Y Y Y Y 8 13 42 0.8 0.7 0.6 81.2 220 0.6 43 Y 1 1 1
48 50 F 155 55 22.89 0 3 N N N N N 6 12 32 0.6 0.7 0.8 114.6 180 0.54 54 N 1 0 1
49 43 M 165 90 33.06 1 3 Y Y Y Y Y 10 14 41 0.6 0.9 0.7 202.1 320 0.52 35 Y 1 1 2
50 53 F 160 45 17.58 1 4 N N N N N 6 7 23 0.6 0.7 0.6 90.6 155 0.55 49 N 1 0 1
KEYS TO MASTER CHART
Ag Age
Sx Sex
H Height
W Weight
BMI Body Mass Index
NY NYHA Functional Class (1= Class I, 2= Class II, 3= Class III, 4= class IV)
HTN Hypertension
DM Diabetes Mellitus
DL Dyslipidemia
Sm Smoking
Alc Alcoholism
HS Duration of Hospital Stay (in days)
Hb Hemoglobin
BU Blood Urea
CrD1 Creatinine on Day 1
CrD2 Creatinine on Day 2
CrCD1 Creatinine clearance  on Day 1
CH Serum Total Cholesterol
CTR Cardiothoracic Ratio
EF Ejection Fraction
SD Systolic Dysfunction
DD Diastolic Dysfunction
Re Readmissions
O Outcome (1= complete recovery, 2= partial recovery, 3= persistent symptoms, 4= death)
  
ABBREVIATIONS 
 
HF  Heart failure 
eGFR  Estimated glomerular filtration rate 
DR  Diuretic resistance 
ADHF  Acute decompensated heart failure 
CRS  Cardiorenal syndrome 
NGAL  Neutrophil gelatinase-associated lipocalin 
PTH  Parathyroid hormone 
CCP  Calcium-phosphate product 
BNP  B-type natriuretic peptide 
CPK-MB Creatine phosphokinase-MB 
ET-1  endothelin-1 
NO-ROS Nitric Oxide- reactive Oxygen species 
SNS  Sympathetic nervous system 
NA/NPY Noe adrenaline/Neuropeptide Y 
NF-KB Nuclear factor kappa B  
CVP  Central venous pressure 
CI  Cardiac index 
WRF  Worsening renal function 
PCWP  Pulmonary capillary wedge pressure 
RAAS  Renin-angiotensin-aldosterone system 
IL  Interleukin 
TGF  Transforming growth factor 
 
